ICYMI: Cancer death rate continues to decline due to treatment advances

This report is the latest to document this progress. A growing body of evidence underscores the role of new medicines in recent accelerated declines in mortality across a range of cancers.One study found, between 2000 and 2016 alone, new cancer medicines were associated with nearly 1.3 million averted cancer deaths across the 15 most common tumor types. In particular, new cancer medicines were associated with nearly 130,000 prevented breast cancer deaths, nearly 400,000 prevented lung cancer deaths, and over 6500 melanoma deaths. While the ACS report highlights tremendous progress in the fight against cancer, it also reveals several alarming trends which threaten this progress and underscores the need for additional efforts to reduce health disparities and address unmet need across a range of cancers. Here are some key takeaways from the report: 
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Medicines in Development Cancer Drug Cost Equity Source Type: news